Affiliation:
1. Department of Biomedical Science and Human Oncology-Pediatric Unit, University of Bari “Aldo Moro”, Bari,Italy
Abstract
Background and Objective:
Immune thrombocytopenia (ITP) is a common bleeding disorder
in childhood. The management of ITP in children is controversial, requiring personalized assessment
of patients and therapeutic choices. Thrombopoietin receptor agonists (TPO-RAs), eltrombopag
and romiplostim, have been shown to be safe and effective for the treatment of pediatric ITP. The aim
of our research is to define the role of thrombopoietin receptor agonists in the management of pediatric
ITP.
Methods:
This review focuses on the use of TPO-RAs in pediatric ITP, in randomized trials and in
clinical routine, highlighting their key role in the management of the disease.
Results:
Eltrombopag and romiplostim appear effective treatment options for children with ITP. Several
clinical studies have assessed that the use of TPO-RAs increases platelet count, decreases bleeding
symptoms and improves health-related quality of life. Moreover, TPO-RAs are well tolerated with
minor side effects.
Conclusion:
Although long term efficacy and safety of TPO-RAs still require further investigations,
their use is gradually expanding in the clinical practice of children with ITP.
Publisher
Bentham Science Publishers Ltd.
Subject
Immunology and Allergy,Endocrinology, Diabetes and Metabolism
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献